Q: What is Haegarda used for?

Haegarda is used to treat hereditary angioedema prophylaxis .

Q: How does Haegarda work?

Restoring Protein Levels Hereditary angioedema (HAE) is a genetic condition caused by a deficiency or dysfunction of a protein called C1 esterase inhibitor. This protein plays a critical role in regulating the immune system and controlling inflammation. Preventing Bradykinin Buildup When C1 esterase inhibitor levels are too low or the protein is not working properly, the body overproduces a substance called bradykinin. Excessive bradykinin causes blood vessels to dilate and leak fluid into the surrounding tissues, leading to the severe swelling attacks seen in HAE. Haegarda works by: Increasing the amount of functional C1 esterase inhibitor in the blood. Regulating the chemical pathways that produce bradykinin. Preventing the leakage of fluid from blood vessels into tissues. By maintaining higher levels of this protein through regular injections, Haegarda helps keep the inflammatory system in balance and reduces the frequency of swelling episodes.

Q: What are the active ingredients in Haegarda?

The active ingredient in Haegarda is C1 esterase inhibitor .

Q: What are the side effects of Haegarda?

Common side effects of Haegarda may include: injection site reactions headache nausea Always consult with a healthcare professional about potential side effects.

Q: What drug class is Haegarda?

Haegarda belongs to the C1 esterase inhibitor drug class.

Q: What is the dosage of Haegarda and how do I take it?

Administration and Frequency Haegarda is injected under the skin (subcutaneously), typically in the abdominal area. It is usually administered twice a week, every few days. This medication is intended for routine prevention and should be used on a regular schedule to be effective. It is not used to treat an acute angioedema attack once it has started. Self-Administration A healthcare provider may train you or a caregiver to prepare and inject the medication at home. It is important to follow the specific instructions provided during training and to use the administration kit supplied with the medicine. Do not attempt to self-inject until you are comfortable with the process. Preparation The medication comes as a powder that must be mixed with a sterile liquid (diluent) before use. Allow the vials to reach room temperature before mixing. When mixing, do not shake the vial; instead, gently swirl it until the powder is completely dissolved. The solution should be clear and colorless to pale yellow. Do not use it if it is cloudy, discolored, or contains visible particles. Once mixed, the solution should be used promptly. Injection Site The injection should be given in the abdomen. Avoid injecting into areas where the skin is bruised, red, scarred, or irritated. It is also recommended to avoid the area immediately surrounding the navel. Missed Dose If you miss a dose, contact your healthcare provider for instructions. Do not use extra medicine or double the dose to make up for a missed one.

Q: Is Haegarda safe during pregnancy and breastfeeding?

Pregnancy It is not known whether Haegarda can cause harm to an unborn baby when administered to a pregnant person. Data from clinical trials are currently insufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse outcomes. In animal reproduction studies, no evidence of harm to the fetus was observed when human C1 esterase inhibitor was administered at doses significantly higher than the recommended human dose. However, animal studies do not always predict how a human will respond. Healthcare providers typically recommend using Haegarda during pregnancy only if the potential benefit justifies the potential risk to the fetus. Breastfeeding It is not known if Haegarda passes into human breast milk, affects milk production, or has any impact on a breastfed infant. Because many drugs are excreted in human milk, caution is advised when using this medication while nursing. Patients should discuss their treatment plan with a healthcare provider to weigh the benefits of breastfeeding against the clinical need for the medication and any potential effects on the child. Factors to consider include the health benefits of breastfeeding for the infant and the mother's clinical requirement for Haegarda to prevent hereditary angioedema attacks.

Q: What forms and strengths does Haegarda come in?

Available Forms Haegarda is supplied as a sterile, lyophilized (freeze-dried) powder in single-use vials. It is intended for subcutaneous administration, which means it is injected into the fatty tissue just under the skin. The medication is typically provided in a kit that includes the following components: A vial containing the freeze-dried protein powder. A vial of Sterile Water for Injection, which is used as a diluent to dissolve the powder. Before administration, the powder must be reconstituted (mixed) with the provided diluent. The resulting solution should be clear and colorless to pale blue. Because the vials are for single use only, any unused portion must be discarded.

Q: What is the FDA approval status of Haegarda?

FDA Approval and Indications Haegarda was approved by the U.S. Food and Drug Administration (FDA) in June 2017. It is indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks. The approval includes use in both adults and pediatric patients 6 years of age and older. Haegarda is intended for preventive use only. It is not indicated for the treatment of acute HAE attacks once they have already begun. Regulatory Classification Haegarda is classified as a C1 esterase inhibitor (human). It is a plasma-derived product, meaning it is manufactured from human blood. As a result, it is subject to specific regulatory requirements for blood products, including rigorous screening and viral inactivation processes to minimize the risk of transmitting infectious agents. Safety and Monitoring There are no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) currently required by the FDA for Haegarda. Regulatory labeling includes standard precautions for plasma-derived products regarding the theoretical risk of pathogen transmission. The FDA continues to monitor the safety profile of the medication through post-marketing surveillance.

Question 1

What is Haegarda?

Accepted Answer

Haegarda is a concentrated form of C1 esterase inhibitor, a protein that occurs naturally in human blood. This protein is essential for controlling certain parts of the immune system and managing inflammation.

The therapy works by replacing or boosting the levels of this protein when it is missing or not functioning correctly. This helps the body maintain normal blood vessel function and prevents the processes that lead to significant swelling.

Question 2

What is Haegarda used for?

Accepted Answer

Haegarda is used to treat hereditary angioedema prophylaxis.

Question 3

How does Haegarda work?

Accepted Answer

Restoring Protein Levels

Hereditary angioedema (HAE) is a genetic condition caused by a deficiency or dysfunction of a protein called C1 esterase inhibitor. This protein plays a critical role in regulating the immune system and controlling inflammation.

Preventing Bradykinin Buildup

When C1 esterase inhibitor levels are too low or the protein is not working properly, the body overproduces a substance called bradykinin. Excessive bradykinin causes blood vessels to dilate and leak fluid into the surrounding tissues, leading to the severe swelling attacks seen in HAE.

Haegarda works by:

Increasing the amount of functional C1 esterase inhibitor in the blood.
Regulating the chemical pathways that produce bradykinin.
Preventing the leakage of fluid from blood vessels into tissues.

By maintaining higher levels of this protein through regular injections, Haegarda helps keep the inflammatory system in balance and reduces the frequency of swelling episodes.

Question 4

What are the active ingredients in Haegarda?

Accepted Answer

The active ingredient in Haegarda is C1 esterase inhibitor.

Question 5

What are the side effects of Haegarda?

Accepted Answer

Common side effects of Haegarda may include:

injection site reactions
headache
nausea

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Haegarda?

Accepted Answer

Haegarda belongs to the C1 esterase inhibitor drug class.

Question 7

What is the dosage of Haegarda and how do I take it?

Accepted Answer

Administration and Frequency

Haegarda is injected under the skin (subcutaneously), typically in the abdominal area. It is usually administered twice a week, every few days. This medication is intended for routine prevention and should be used on a regular schedule to be effective. It is not used to treat an acute angioedema attack once it has started.

Self-Administration

A healthcare provider may train you or a caregiver to prepare and inject the medication at home. It is important to follow the specific instructions provided during training and to use the administration kit supplied with the medicine. Do not attempt to self-inject until you are comfortable with the process.

Preparation

The medication comes as a powder that must be mixed with a sterile liquid (diluent) before use.
Allow the vials to reach room temperature before mixing.
When mixing, do not shake the vial; instead, gently swirl it until the powder is completely dissolved.
The solution should be clear and colorless to pale yellow. Do not use it if it is cloudy, discolored, or contains visible particles.
Once mixed, the solution should be used promptly.

Injection Site

The injection should be given in the abdomen. Avoid injecting into areas where the skin is bruised, red, scarred, or irritated. It is also recommended to avoid the area immediately surrounding the navel.

Missed Dose

If you miss a dose, contact your healthcare provider for instructions. Do not use extra medicine or double the dose to make up for a missed one.

Question 8

Is Haegarda safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not known whether Haegarda can cause harm to an unborn baby when administered to a pregnant person. Data from clinical trials are currently insufficient to establish a drug-associated risk for major birth defects, miscarriage, or other adverse outcomes.

In animal reproduction studies, no evidence of harm to the fetus was observed when human C1 esterase inhibitor was administered at doses significantly higher than the recommended human dose. However, animal studies do not always predict how a human will respond. Healthcare providers typically recommend using Haegarda during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known if Haegarda passes into human breast milk, affects milk production, or has any impact on a breastfed infant. Because many drugs are excreted in human milk, caution is advised when using this medication while nursing.

Patients should discuss their treatment plan with a healthcare provider to weigh the benefits of breastfeeding against the clinical need for the medication and any potential effects on the child. Factors to consider include the health benefits of breastfeeding for the infant and the mother's clinical requirement for Haegarda to prevent hereditary angioedema attacks.

Question 9

What forms and strengths does Haegarda come in?

Accepted Answer

Available Forms

Haegarda is supplied as a sterile, lyophilized (freeze-dried) powder in single-use vials. It is intended for subcutaneous administration, which means it is injected into the fatty tissue just under the skin.

The medication is typically provided in a kit that includes the following components:

A vial containing the freeze-dried protein powder.
A vial of Sterile Water for Injection, which is used as a diluent to dissolve the powder.

Before administration, the powder must be reconstituted (mixed) with the provided diluent. The resulting solution should be clear and colorless to pale blue. Because the vials are for single use only, any unused portion must be discarded.

Question 10

What is the FDA approval status of Haegarda?

Accepted Answer

FDA Approval and Indications

Haegarda was approved by the U.S. Food and Drug Administration (FDA) in June 2017. It is indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks. The approval includes use in both adults and pediatric patients 6 years of age and older.

Haegarda is intended for preventive use only. It is not indicated for the treatment of acute HAE attacks once they have already begun.

Regulatory Classification

Haegarda is classified as a C1 esterase inhibitor (human). It is a plasma-derived product, meaning it is manufactured from human blood. As a result, it is subject to specific regulatory requirements for blood products, including rigorous screening and viral inactivation processes to minimize the risk of transmitting infectious agents.

Safety and Monitoring

There are no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) currently required by the FDA for Haegarda. Regulatory labeling includes standard precautions for plasma-derived products regarding the theoretical risk of pathogen transmission. The FDA continues to monitor the safety profile of the medication through post-marketing surveillance.

Question 11

What should I know about Haegarda and cost?

Accepted Answer

Insurance and Prior Authorization

Haegarda is a specialty medication, and most insurance plans require prior authorization before they will cover the cost. This process involves your healthcare provider submitting documentation to the insurance company to prove the medical necessity of the drug for preventing hereditary angioedema (HAE) attacks.

Specialty Pharmacy Requirements

Because Haegarda requires specific handling and storage, it is typically dispensed through a specialty pharmacy rather than a standard retail pharmacy. These pharmacies often provide additional support services, such as coordinating delivery and explaining insurance benefits.

Financial Assistance Programs

The manufacturer of Haegarda offers support programs to help reduce the financial burden for patients. These may include:

Copay Assistance: Eligible patients with commercial insurance may qualify for programs that lower out-of-pocket costs.
Patient Assistance Programs: For individuals without insurance or those who are underinsured, the manufacturer may provide the medication at a reduced cost or for free based on financial need and eligibility criteria.

The total cost of treatment also depends on the prescribed dose, which is calculated based on the patient's body weight (60 International Units per kilogram of body weight).

Haegarda

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Haegarda

Hospitals.net Disclosure